Conjugation of mono and di-GalNAc sugars enhances the potency of antisense oligonucleotides via ASGR mediated delivery to hepatocytes-Reference-Cited by-同舟云学术

Conjugation of mono and di-GalNAc sugars enhances the potency of antisense oligonucleotides via ASGR mediated delivery to hepatocytes

Published:2016-08 Issue:15 Volume:26 Page:3690-3693
ISSN:0960-894X
Container-title:Bioorganic & Medicinal Chemistry Letters
language:en
Short-container-title:Bioorganic & Medicinal Chemistry Letters

Author:

Kinberger Garth A.,Prakash Thazha P.^ORCID,Yu Jinghua,Vasquez Guillermo,Low Audrey,Chappell Alfred,Schmidt Karsten,Murray Heather M.,Gaus Hans,Swayze Eric E.,Seth Punit P.^ORCID

Publisher

Elsevier BV

Subject

Organic Chemistry,Clinical Biochemistry,Drug Discovery,Pharmaceutical Science,Molecular Biology,Molecular Medicine,Biochemistry

Reference34 articles.

1. RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform

2. Determination of the Role of the Human RNase H1 in the Pharmacology of DNA-like Antisense Drugs

3. 2′-Carbohydrate modifications in antisense oligonucleotide therapy: importance of conformation, configuration and conjugation

4. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug development advances in human genetics‐based targets;MedComm;2024-02

2. Unprecedented selectivity for homologous lectin targets: differential targeting of the viral receptors L-SIGN and DC-SIGN;Chemical Science;2024

3. Predicting the pharmacokinetics and pharmacodynamics of antisense oligonucleotides: an overview of various approaches and opportunities for PBPK/PD modelling;Expert Opinion on Drug Metabolism & Toxicology;2023-11-18

4. Enhancing the Effectiveness of Oligonucleotide Therapeutics Using Cell-Penetrating Peptide Conjugation, Chemical Modification, and Carrier-Based Delivery Strategies;Pharmaceutics;2023-04-03

5. Development of Novel siRNA Therapeutics: A Review with a Focus on Inclisiran for the Treatment of Hypercholesterolemia;International Journal of Molecular Sciences;2023-02-16